Thanks for your take on N8. The parallels between the two programs was pretty remarkable. The other company listed in the table appears to be working on other indications and the only overlap that I saw (a cursory look) was that of diabetic foot infections. Win, lose, or draw, it'll be interesting to follow this technology to market.